Top Page
Rhythm Biosciences Ltd.
(Sydney:RHY)
Rhythm Biosciences Ltd. (RHY) vs. iShares MSCI Australia ETF (EWA)
Rhythm Biosciences Ltd. Business Overview & Revenue Model
Rhythm Biosciences Ltd. Financial Statement Overview
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 71.37K | 3.19M | 1.69M | 3.10M | 2.43M | 1.11M |
| Gross Profit | -4.57M | 2.97M | -1.36M | 2.91M | -101.48K | 961.86K |
| EBITDA | -7.98M | -3.53M | -8.35M | -11.11M | -11.10M | -6.46M |
| Net Income | -6.68M | -3.83M | -6.86M | -8.22M | -8.79M | -6.61M |
Balance Sheet | ||||||
| Total Assets | 3.10M | 2.83M | 1.52M | 7.70M | 8.44M | 3.07M |
| Cash, Cash Equivalents and Short-Term Investments | 1.73M | 1.48M | 754.50K | 4.17M | 7.60M | 2.27M |
| Total Debt | 262.44K | 1.11M | 163.82K | 84.61K | 170.14K | 0.00 |
| Total Liabilities | 955.41K | 2.17M | 651.54K | 1.82M | 1.07M | 1.36M |
| Stockholders Equity | 2.14M | 659.89K | 867.17K | 5.87M | 7.37M | 1.71M |
Cash Flow | ||||||
| Free Cash Flow | -6.14M | -2.94M | -6.22M | -7.06M | -6.24M | -5.47M |
| Operating Cash Flow | -6.11M | -2.92M | -6.14M | -6.96M | -6.21M | -5.40M |
| Investing Cash Flow | -24.23K | -582.96K | -82.28K | -99.12K | -27.01K | -68.27K |
| Financing Cash Flow | 3.41M | 4.19M | 2.80M | 3.63M | 11.85M | 5.90M |
Rhythm Biosciences Ltd. Technical Analysis
Rhythm Biosciences Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$231.34M | -7.39 | -111.23% | ― | 12.96% | 40.81% | |
45 Neutral | AU$42.40M | -2.45 | -164.22% | ― | ― | 23.85% | |
43 Neutral | AU$67.63M | -4.75 | -501.54% | ― | ― | 56.42% | |
43 Neutral | AU$5.67M | -0.55 | ― | ― | -56.35% | 42.80% | |
41 Neutral | AU$19.99M | -2.23 | -36.16% | ― | 62.81% | 16.37% | |
38 Underperform | AU$45.75M | -3.01 | -37.14% | ― | 2.33% | 12.50% |
Rhythm Biosciences Ltd. Corporate Events
Rhythm Biosciences has secured National Association of Testing Authorities accreditation for its ColoSTAT blood-based colorectal cancer test within its ISO 15189:2022-certified Parkville laboratory. This recognition confirms that both the facility and the ColoSTAT assay meet internationally accepted standards for medical testing quality, competence, and result traceability.
With ColoSTAT now an accredited clinical laboratory service, Rhythm can begin offering the test to referring clinicians and patients as part of its commercial launch in Australia. The accreditation is also a key step toward pursuing Medicare Benefits Schedule reimbursement, which could support broader physician uptake and integration of ColoSTAT into routine colorectal cancer screening pathways.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.19 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
Rhythm Biosciences has applied to the ASX for quotation of 90,842 new fully paid ordinary shares. The additional securities arise from the exercise or conversion of existing options or other convertible instruments, modestly increasing the company’s listed share capital and slightly broadening its equity base for investors.
The issuance of these shares reflects the uptake of previously granted securities and may provide incremental liquidity in Rhythm Biosciences’ stock on the market. While the scale of this quotation is limited, it signals ongoing engagement with capital markets and may marginally adjust ownership positions among existing shareholders.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.19 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
Rhythm Biosciences has signed a 12‑month supply and distribution agreement with UK-based Digistain Limited to commercialise its geneType genetic test portfolio in Southeast Asia, starting with the Philippines as the initial launch market. The deal provides structured per-test pricing, minimum volume commitments, and renewal options, giving Rhythm a clear revenue line of sight and establishing its first contracted commercial entry into this underserved region.
By leveraging Digistain’s established cancer diagnostics networks and sub-distribution channels, including links with Precision Healthcare PTE, Rhythm gains an immediate regional footprint without building its own infrastructure. The agreement supports the company’s dual-platform and international expansion strategy, positioning geneType as a cost-effective, clinically validated risk assessment solution in a large, growing market with increasing healthcare spending and low penetration of advanced genetic testing.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.22 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
Rhythm Biosciences has issued 413,793 new ordinary shares on 27 February 2026 and lodged a cleansing notice under section 708A(5)(e) of the Corporations Act, confirming the issuance was made without a disclosure document. The company states it is compliant with its continuous disclosure and financial reporting obligations, and that there is no excluded information requiring disclosure, ensuring the new shares can be freely traded and maintaining regulatory transparency for investors.
The cleansing notice supports Rhythm’s capital management and market activities by enabling efficient share issuance while preserving investor protections under Australian securities law. This administrative step reinforces the company’s adherence to governance standards as it pursues commercialisation of its cancer diagnostics portfolio, which may influence stakeholder confidence and the liquidity of its securities.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.20 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
Rhythm Biosciences Ltd. has applied for quotation of 413,793 new ordinary fully paid shares on the Australian Securities Exchange, with an issue date of 27 February 2026. The additional securities, linked to a previously announced transaction, will modestly expand the company’s share base and may provide incremental capital or support for its ongoing corporate and operational activities, while slightly diluting existing shareholders.
The move underscores Rhythm Biosciences’ continued use of equity markets to support its business objectives and maintain its listing compliance. For investors and other stakeholders, the quotation of these new shares reflects routine capital management and may signal ongoing funding or strategic initiatives aligned with the company’s bioscience development plans.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.20 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
Rhythm Biosciences Ltd. has applied to the ASX for quotation of 61,901 new ordinary fully paid shares, which are being issued following the exercise or conversion of existing options or other convertible securities. The modest increase in quoted securities slightly expands the company’s issued capital base and may reflect ongoing shareholder participation in its equity incentive or financing structures.
While the volume of new shares is relatively small in the context of a listed company, the move formalizes their admission to trading on the ASX and maintains transparency around Rhythm Biosciences’ capital structure. This technical listing step ensures the newly issued securities become fully tradable on-market, providing liquidity to holders and marginally diluting existing shareholders.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.20 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
Rhythm Biosciences has secured a binding underwriting agreement with CPS Capital Group to partially underwrite the exercise of its listed options, guaranteeing a minimum of $4.5 million and up to $6 million in funding before costs. The underwriter will subscribe for shares corresponding to any unexercised options at expiry, with the flexibility to appoint sub-underwriters and extend participation if demand exceeds the underwritten amount.
The capital raised will support the commercial rollout of the ColoSTAT and geneType diagnostic platforms as well as general working capital, reinforcing the company’s funding certainty as it pursues domestic and international growth. The structure of the deal, including issuance of shortfall shares and options to the underwriter within existing placement capacities, is designed to strengthen Rhythm Biosciences’ balance sheet while advancing its commercialisation strategy across key markets.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.20 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
Rhythm Biosciences Limited has applied for quotation on the ASX of 300,137 new fully paid ordinary shares under code RHY. The new securities, issued on 20 February 2026 following the exercise or conversion of existing options or other convertible instruments, will modestly increase the company’s listed share capital and may have a small dilutive effect for existing shareholders.
The application, lodged as an Appendix 2A new announcement, reflects routine capital management activity within the company’s ASX listing framework. While the release does not provide operational or strategic updates, it signals continued engagement with capital markets and incremental expansion of Rhythm Biosciences’ equity base.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.20 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
Rhythm Biosciences has launched its ColoSTAT Access Program in Australia, enrolling the first physician participant and formally moving the blood-based colorectal cancer test from clinical development into structured commercial deployment. The program provides an initial no-cost allocation of tests to up to 20 clinicians to establish safe, routine ordering and usage processes before transitioning them to standard commercial pricing.
Through this controlled rollout, Rhythm aims to demonstrate ColoSTAT’s operational readiness, generate real-world performance and utilisation data, and refine workflows for broader market deployment. The initiative seeks to validate clinician demand for a less invasive blood test alternative to existing colorectal cancer screening methods, potentially improving screening participation and supporting future reimbursement and partner engagement.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.23 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
Rhythm Biosciences has reminded holders of its ASX-listed RHYO options that these securities must be exercised by 5.00pm Melbourne time on 31 March 2026 at an exercise price of $0.20 per option, with each option converting into one fully paid RHY share. The company noted that trading in RHYO options will cease on 25 March 2026 and that any options not exercised by the deadline will automatically lapse and expire worthless, clarifying the administrative steps for investors but leaving the options ununderwritten, which may influence how many convert into equity.
Option holders can choose either to exercise some or all of their RHYO options via BPAY or EFT using personalised details from the Automic investor portal, or to take no action and allow the options to lapse. The reminder places the onus on investors to manage payment timing and clearing limits ahead of the expiry, with no brokerage costs on exercise but a hard cut-off after which no entitlement to subscribe for RHY shares at the fixed price will remain.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.23 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
Rhythm Biosciences has signed a multi-year commercial supply agreement with US-based Quansys Biosciences to manufacture ColoSTAT® consumable reagent kits at commercial scale. The deal formalises a two-year collaboration and secures ISO13485-certified, quality-assured production capacity, flexible scaling with demand, and established global logistics, underpinning the ColoSTAT® Access Program and future commercial rollout. By locking in reliable supply, scalable infrastructure and initial fixed pricing for cost predictability, the agreement marks a significant operational milestone that reduces manufacturing and quality risk and strengthens Rhythm’s readiness for broader market entry in colorectal cancer diagnostics.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
Rhythm Biosciences has entered a strategic partnership with the Australian Genome Research Facility to establish an Australian-based reference laboratory for its geneType genotyping services, enabling local processing of more than 100,000 tests annually. The deal is designed to cut turnaround times and shipping costs, improve service responsiveness, and keep patient samples and data within Australian regulatory frameworks, a key factor for privacy-focused clinicians and institutional buyers. Working alongside its existing US partner Gene by Gene, Rhythm is creating a dual-laboratory, capital‑efficient operating model that builds redundancy, reduces supply chain risk and supports commercial-scale deployment. The AGRF collaboration, expected to begin processing in Q3 FY26, underpins Rhythm’s plans to expand into Southeast Asia in the second half of 2026 by using Australia as a scalable regional processing hub, strengthening its competitiveness for institutional contracts where local processing, data sovereignty and rapid turnaround are critical selection criteria.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.16 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
Rhythm Biosciences has entered a strategic partnership with US-based digital oncology platform CancerIQ, integrating its geneType™ Cancer Risk Assessment into a cloud-based system already deployed across more than 65 health systems and 345 clinics. The deal gives Rhythm immediate access to millions of US patients via embedded clinical workflows, enabling seamless electronic ordering with automated data population, reducing administrative barriers and eliminating the need for a costly direct sales force. By broadening CancerIQ’s test menu with polygenic and multifactor risk modelling, Rhythm strengthens its positioning in the competitive cancer diagnostics market and creates a clear pathway to recurring test revenues and repeat testing as patients progress through cancer screening pathways, potentially accelerating its US commercialisation and long-term revenue growth.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.16 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
Rhythm Biosciences has begun commercialising its ColoSTAT® blood test in Australia after securing ISO 15189:2022 accreditation, marking its first revenue-generating product and aiming to improve triage for more than 800,000 symptomatic colonoscopy patients annually, while easing pressure on the healthcare system. The company also advanced its geneType™ portfolio with early delivery of a next-generation colorectal cancer risk assessment test, peer-reviewed validation of its ovarian cancer model in Harvard’s large Nurses’ Health Study, new US-focused partnerships such as with CatchBio, and an evaluation agreement with NHS England, all underpinned by a strengthened balance sheet, removal of debt, and new board leadership as it shifts decisively from R&D to commercial growth.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.16 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
Rhythm Biosciences has announced peer‑reviewed publication of clinical validation data for its first-generation ColoSTAT singleplex blood test for colorectal cancer, showing 81.3% sensitivity and 91% specificity in a 989‑patient, multi-centre study, with performance comparable to stool-based tests used in Australia’s national bowel cancer screening program. The results underpin a near-term commercial push into the large symptomatic patient triage market, where ColoSTAT could help prioritise up to 800,000 annual colonoscopy referrals in Australia by distinguishing cancer from benign gastrointestinal conditions, potentially halving unnecessary procedures and related costs, and supporting future regulatory approvals and partnership discussions for the optimised second-generation multiplex test.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.16 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
Rhythm Biosciences has issued 1,000,000 new ordinary shares on 16 January 2026 and has lodged a cleansing notice confirming that the shares were issued without a prospectus under the Corporations Act disclosure exemptions. The company states it remains compliant with its financial reporting and continuous disclosure obligations and that there is no excluded information requiring disclosure, providing investors with assurance around regulatory compliance as it continues to advance and commercialise its cancer diagnostics offerings, including its ColoSTAT colorectal cancer blood test.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
Rhythm Biosciences Limited has applied to the ASX for quotation of 1,000,000 new ordinary fully paid shares, with an issue date of 16 January 2026. The additional securities, issued under a previously announced transaction, will expand the company’s listed share base and may modestly increase liquidity for existing and new investors.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
Rhythm Biosciences has disclosed the cessation of 750,000 fully paid ordinary employee performance rights (ASX code: RHYAR), which lapsed after the conditions attached to those rights were not met or became incapable of being satisfied as of 13 January 2026. The lapse reduces the pool of potential future share issuances tied to employee incentives, modestly tightening the company’s prospective capital base and reflecting adjustments to its employee equity scheme without impacting existing shareholders’ current holdings.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.13 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
Rhythm Biosciences has commercially launched an enhanced version of its geneType colorectal cancer risk assessment test, which now integrates genetic, clinical and lifestyle factors, along with gender-specific variables, to deliver improved risk stratification across both men and women, including younger adults. Backed by peer-reviewed validation showing stronger performance than traditional models, the upgraded test is intended to identify a broader cohort of higher-risk individuals earlier, support more targeted screening pathways and boost participation in bowel cancer screening programs, while also creating a complementary funnel for the company’s ColoSTAT blood-based colorectal cancer detection test and strengthening its positioning in predictive oncology and early detection markets.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.13 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
Rhythm Biosciences Ltd has issued 31,250 unquoted options under an employee incentive scheme, with each option exercisable at A$0.20 and expiring on 30 November 2027, as notified in an Appendix 3G filing to the ASX. The move underscores the company’s ongoing use of equity-based incentives to attract and retain key staff, aligning employee interests with shareholders and potentially modestly increasing the company’s fully diluted capital base if the options are exercised.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
Rhythm Biosciences has notified the ASX of a proposed issue of up to 625,000 ordinary fully paid shares under a placement or similar capital-raising mechanism, with the new securities expected to be issued on 2 February 2026. The move signals an intention to bolster the company’s capital base, which may support ongoing operations and development activities, and could modestly dilute existing shareholders while potentially strengthening Rhythm’s financial position ahead of future milestones.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
Rhythm Biosciences Limited has announced a proposed issuance of up to 1,000,000 fully paid ordinary securities, with a scheduled issue date of January 30, 2026. This strategic move could provide the company with additional capital to support its ongoing development efforts and strengthen its positioning in the competitive biotechnology industry.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
Rhythm Biosciences Ltd has initiated the commercialization of its ColoSTAT® test, a blood-based diagnostic tool for colorectal cancer, following an updated ISO15189:2022 accreditation. This marks a significant milestone as ColoSTAT® addresses the unmet clinical need for patients where stool-based testing is unsuitable or not preferred. The test will be rolled out through Rhythm’s certified laboratory in Melbourne, with immediate domestic market activities. The company plans to conduct a variation to scope assessment with the National Association of Testing Authorities in January 2026, which would further establish ColoSTAT® as an accredited laboratory service, enhancing clinician confidence and commercial scalability.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.09 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
Rhythm Biosciences Ltd announced the departure of its Chief Financial Officer, Mr. Todd Perkinson, effective December 19, 2025. This change in leadership comes as the company continues to focus on its mission of providing innovative diagnostic solutions for early cancer detection. The departure could impact the company’s financial strategy and operations, but the board expressed gratitude for Mr. Perkinson’s contributions.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.09 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.